Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
about
Preoperative chemotherapy for women with operable breast cancerThe role of preoperative systemic treatment in patients with breast cancerAdjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineDocetaxel/anthracycline combinations for breast cancer treatmentCarbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline.Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials.Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in womNEO adjuvant chemotherapy in breast cancer: What have we learned so far?CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer.Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients.Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial).Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.A Canadian national expert consensus on neoadjuvant therapy for breast cancer: linking practice to evidence and beyondTargeting thyroid hormone receptor beta in triple-negative breast cancer.Neoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium.Treatment-induced cell cycle kinetics dictate tumor response to chemotherapyProtein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trialA network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancerNeoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials.Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival.Neoadjuvant chemotherapy and pathologic response: a retrospective cohortNeoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future.Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.Are we HER-ting for innovation in neoadjuvant breast cancer trial design?Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer.Neoadjuvant systemic treatment of breast cancer.Surgical treatment of primary breast cancer in the neoadjuvant setting.Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.Recent Advances in the Neoadjuvant Treatment of Breast Cancer.Inflammatory breast cancer-comparing the effectivity of preoperative docetaxel-epirubicine protocol to conventional antracycline-containing chemotherapy to achieve clinical benefit and complete pathological response.A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score.Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer.Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical OncTime interval of neoadjuvant chemotherapy to surgery in breast cancer: how long is acceptable?Taxane therapy for early stage breast cancer.A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.Dose-dense primary chemotherapy, as part of multidisciplinary treatment, for inoperable stage III B breast cancer--long-term results of a phase II trial.From clinical trials to clinical practice: outcome of NSABP-B27 neoadjuvant chemotherapy regimen for high-risk early-stage breast cancer.Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer.
P2860
Q24245281-DAE338EA-5B1D-4025-84DD-8DEE3D98A832Q26746034-9E27678F-8C21-44E6-9005-D9C090D654EBQ26853619-49C850D4-DEB6-4EBE-8D45-CF24A0EA5C5AQ28288899-BA6B737F-E38E-4212-B87E-A5A4D5227433Q33759404-A6EB6D15-5E9A-4D21-814C-24B08AAE77B6Q33785011-0472FFD8-A74D-429B-A7FA-958232527BB3Q33904763-3061ACC6-3439-41FD-A164-D9EB52DE5738Q34138174-A03D4D53-2C31-4FC2-A227-16B1C40536CEQ34438511-356A0C6D-3A10-4632-878B-66A28C693E02Q34779690-530D5338-2DAB-4B84-9A1D-28C47010FAEAQ35218744-B1204D9A-B5FB-40E6-8E27-F73A0889A0D4Q35222636-15986998-5795-4358-87FF-7FE077680C63Q35239617-0900E8EF-B9D7-4B8C-AFD6-0FC59CBA2680Q35564703-048538C1-A915-40D6-8DFE-B6769A5BF330Q35667692-458A7D9A-AD62-48CB-9463-625E3AC34173Q35740145-C459C515-BB36-4044-AD56-8FAE94822611Q35889568-D4D37396-CC11-4992-A5FF-98DF120DEF59Q36181844-B104DA2D-C2A6-41D0-9360-C9EA40925BEEQ36221963-E26D97FF-033F-4B15-B497-9AB6A583597BQ36848102-C3F50327-7B98-400F-9D08-83E049841129Q36935858-998E38A1-72C4-4804-A0C3-C6579739EDC3Q37145188-F60BE61D-EE4E-4338-BE59-F6136CF015F9Q37180350-2436C3F1-9835-4C37-B352-3D27A123FD43Q37205521-45649DF7-B644-4B0F-BE37-250D8E1FDACDQ37208730-D922A2E9-E32C-4201-83C2-C98F1BE85C11Q37845317-74D51571-F339-4788-A006-2B8CCACA4B03Q38212607-8A860EFD-99D9-4645-AC0C-9F3AB7A93C88Q38682028-7C20BBCA-30A1-436C-AC21-4ED2E85F6B20Q38687392-4D928968-3811-442E-A2FC-FC4E1787BAABQ39962699-081D4214-A057-4FB3-95CC-E053067DA732Q41179097-6EBCA4E1-9BCA-486F-B945-4CE138B9DD38Q41602353-3969D377-305B-4D4B-8B76-DA1A39BE0362Q42223844-2D92296F-1964-4F2A-AF97-92D263EEB91AQ42323665-FE5D0975-5E2A-4A74-93F2-4F5978A8A96FQ43267052-83066BE8-9AAB-4361-AE2F-E436E558BF56Q46435201-0FE43E8C-7ABE-4855-8A05-BE25F704F348Q46817262-6D5603D5-B99E-4331-B3FE-88F5E7DB2034Q46902873-943B19E1-9E27-4076-A739-8B640A315B2CQ47713074-D6C51C66-8534-4404-AD84-4B7EAC551193Q55073332-1F485D7D-1E0B-4C0C-A859-0AB520274ADC
P2860
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Phase III randomized trial of ...... perative oncology group study.
@en
Phase III randomized trial of ...... perative oncology group study.
@nl
type
label
Phase III randomized trial of ...... perative oncology group study.
@en
Phase III randomized trial of ...... perative oncology group study.
@nl
prefLabel
Phase III randomized trial of ...... perative oncology group study.
@en
Phase III randomized trial of ...... perative oncology group study.
@nl
P2093
P356
P1476
Phase III randomized trial of ...... perative oncology group study.
@en
P2093
Alison L Jones
Andrew W Hutcheon
Ann Yellowlees
Christopher J Gallagher
David A Cameron
Elizabeth Foster
Helena Earl
Janine L Mansi
John Crown
Martin Highley
P304
P356
10.1200/JCO.2005.06.156
P407
P577
2005-05-01T00:00:00Z